Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco
- PMID: 40656144
- PMCID: PMC12245639
- DOI: 10.11604/pamj.2025.50.105.43868
Epidemiological and molecular profile of breast cancer: a retrospective study in Casablanca, Morocco
Abstract
Introduction: breast cancer is a major public health concern in Morocco due to delayed diagnosis and treatment, largely due to its high incidence. It is the most prevalent cancer in women. This study aimed to report the epidemiological and the molecular profile of invasive breast carcinoma using surrogate immunohistochemical markers.
Methods: during 24 months from 1st January 2020 to 31st December 2021 at the Pathology Department of Ibn Rochd University Hospital of Casablanca, Morocco, we conducted a retrospective study comprised 1,558 breast cancer cases, including male patients. The generated data was analyzed using GraphPad Prism 8 software to define the epidemiological and molecular features of breast cancer.
Results: this epidemiological study reveals that the mean age of patients was 52 ± 12.27 years. The most common histological type is invasive breast carcinoma of no special type, which accounts for 90.5% (n=1,410) of cases. Regarding Ellis and Elston modified Scarff-Bloom-Richardson (SBR) grade, grade III was the most common, 52.2% (n=521), followed by grade II, 44% (n=438), and grade I, 3.8% (n=38), as assessed by the SBR grade. The molecular classification results indicate that luminal B was the most common subtype at 52.2% (n=441), followed by triple-negative at 19.6% (n=166), with HER2 phenotype representing 17.4% (n=147) and luminal A at 10.8% (n=91).
Conclusion: this study highlights that invasive breast carcinoma of no special type is the most common type, with grade III tumors being the most frequent. The majority of cases were luminal B, underscoring the need for targeted therapeutic strategies.
Keywords: Breast cancer; Morocco; epidemiology; invasive carcinoma; molecular profile.
Copyright: Khadija Khadiri et al.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status.Breast J. 2023 Nov 30;2023:6621409. doi: 10.1155/2023/6621409. eCollection 2023. Breast J. 2023. PMID: 38075551 Free PMC article.
-
Clinicopathological and molecular subtypes of breast cancer in the Eastern Cape, South Africa: A two-year retrospective study.PLoS One. 2025 Jul 21;20(7):e0325387. doi: 10.1371/journal.pone.0325387. eCollection 2025. PLoS One. 2025. PMID: 40690467 Free PMC article.
-
Interventions for promoting habitual exercise in people living with and beyond cancer.Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3. Cochrane Database Syst Rev. 2018. PMID: 30229557 Free PMC article.
-
Prophylactic mastectomy for the prevention of breast cancer.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. doi: 10.1002/14651858.CD002748.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. doi: 10.1002/14651858.CD002748.pub3. PMID: 15495033 Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
References
-
- International Agency for Research on Cancer Globocan 2020: New Global Cancer Data. 2020
-
- Aboulhoda F, Hadrya F, Bejja F, Dahou B, Erefai O, Soulaymani A, et al. Epidemiological and Histological Profile of Breast Cancer in the Ghrab Chrarda Bni Hsein Region, Morocco. Bangladesh Journal of Medical Science. 2024 Oct 2;23(4):1129–36.
-
- World Health Organization (WHO) 2018. Dernières données mondiales sur le cancer: le fardeau du cancer atteint 18, 1 millions de nouveaux cas et 9, 6 millions de décès par cancer en 2018.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous